Feasibility of Long-Term Patient Self-Reporting of Toxicities From Home via the Internet During Routine Chemotherapy
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Purpose: Patient-reported outcomes are increasingly used in routine outpatient cancer care to guide clinical decisions and enhance communication. Prior evidence suggests good patient compliance with reporting at scheduled clinic visits, but there is limited evidence about compliance with long-term longitudinal reporting between visits. Patients and Methods: Patients receiving chemotherapy for lung, gynecologic, genitourinary, or breast cancer at a tertiary cancer center, with access to a home computer and prior e-mail experience, were asked to self-report seven symptomatic toxicities via the Web between visits. E-mail reminders were sent to participants weekly; patient-reported high-grade toxicities triggered e-mail alerts to nurses; printed reports were provided to oncologists at visits. A priori threshold criteria were set to determine if this data collection approach merited further development based on monthly (≥ 75% participants reporting at least once per month on average) and weekly compliance rates (60% at least once per week). Results: Between September 2006 and November 2010, 286 patients were enrolled (64% were women; 88% were white; median age, 58 years). Mean follow-up was 34 weeks (range, 2 to 214). On average, monthly compliance was 83%, and weekly compliance was 62%, without attrition until the month before death. Greater compliance was associated with older age and higher education but not with performance status. Compliance was greatest during the initial 12 weeks. Symptomatic illness and technical problems were rarely barriers to compliance. Conclusion: Monthly compliance with home Web reporting was high, but weekly compliance was lower, warranting strategies to enhance compliance in routine care settings.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis
Verstovsek, S., Mesa, R. A., Gotlib, J., Levy, R. S., Gupta, V., DiPersio, J. F., Catalano, J. V., Deininger, M., Miller, C., Silver, R. T., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110557 · Cited by 2,103 · cited 2×
“Previous work has demonstrated that in industry-sponsored clinical trials, remote electronic self-reporting (ie, home reporting) is feasible and can have high levels of compliance.(21-23) However, these trials were conducted in carefully selected and JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T VOLUME 31 N…”
BackgroundJAK inhibition with ruxolitinib versus best available therapy for myelofibrosis
Harrison, C., Kiladjian, J.-J., Al-Ali, H. K., Gisslinger, H., Waltzman, R., Stalbovskaya, V., McQuitty, M., Hunter, D. S., Levy, R., Knoops, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1110556 · Cited by 1,825 · cited 2×
“Previous work has demonstrated that in industry-sponsored clinical trials, remote electronic self-reporting (ie, home reporting) is feasible and can have high levels of compliance.(21-23) However, these trials were conducted in carefully selected and JOURNAL OF CLINICAL ONCOLOGY O R I G I N A L R E P O R T VOLUME 31 N…”
BackgroundVelikova, G., Booth, L., Smith, A. B., Brown, P. M., Lynch, P., Brown, J. M., & Selby, P. J. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.06.078 · Cited by 1,382
Detmar, S. B., Muller, M. J., Schornagel, J. H., Wever, L. D. V., & Aaronson, N. K. (2002) · JAMA · doi:10.1001/jama.288.23.3027 · Cited by 1,011 · cited 1×
“a growing body of evidence demonstrating that PROs improve quality of care and patient-provider communication.(2,14-16) Moreover, PROs can flag symptoms that providers systematically miss or downgrade, such as nausea, neuropathy, fatigue, dyspnea, and anorexia; failure to note these symptoms may result in subsequent h…”
BackgroundBasch, E., Iasonos, A., McDonough, T., Barz, A., Culkin, A., Kris, M. G., Scher, H. I., & Schrag, D. (2006) · The Lancet Oncology · doi:10.1016/s1470-2045(06)70910-x · Cited by 653 · cited 1×
“Moreover, PROs can flag symptoms that providers systematically miss or downgrade, such as nausea, neuropathy, fatigue, dyspnea, and anorexia; failure to note these symptoms may result in subsequent health problems that otherwise could have been prevented.(17-20) Previous work has demonstrated that in industry-sponsore…”
BackgroundSelf-citationThe Missing Voice of Patients in Drug-Safety Reporting
Basch, E. (2010) · New England Journal of Medicine · doi:10.1056/nejmp0911494 · Cited by 646 · cited 1×
“The use of patient-reported outcomes (PROs) in routine clinical practice has received recent interest by health care providers for its potential to improve symptom management, communication, and efficiency of clinical operations.(1-6) Medical, surgical, and radiation oncology practices are integrating PROs into their…”
BackgroundSelf-citationCleeland, C. S., Wang, X. S., Shi, Q., Mendoza, T. R., Wright, S. L., Berry, M. D., Malveaux, D., Shah, P. K., Gning, I., Hofstetter, W. L., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.29.8315 · Cited by 341 · cited 2×
“Between-visit reporting is of particular interest because of the ability to monitor patients when they are away from the clinic but experiencing symptoms that merit changes in management.(3,26-31) Therefore, we sought to examine long-term patient compliance rates with self-reporting of seven common symptomatic toxicit…”
Background
Cited by
Basch, E., Deal, A. M., Kris, M. G., Scher, H. I., Hudis, C. A., Sabbatini, P., Rogak, L., Bennett, A. V., Dueck, A. C., Atkinson, T. M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2015.63.0830 · Cited by 2,593
Self-citationDueck, A. C., Mendoza, T. R., Mitchell, S. A., Reeve, B. B., Castro, K. M., Rogak, L. J., Atkinson, T. M., Bennett, A. V., Denicoff, A. M., O'Mara, A. M., et al. (2015) · JAMA Oncology · doi:10.1001/jamaoncol.2015.2639 · Cited by 1,030
Self-citationHowell, D., Molloy, S., Wilkinson, K., Green, E., Orchard, K., Wang, K., & Liberty, J. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv181 · Cited by 536
Synthetic Lethality and Cancer Therapy: Lessons Learned from the Development of PARP Inhibitors
Lord, C. J., Tutt, A. N. J., & Ashworth, A. (2015) · Annual Review of Medicine · doi:10.1146/annurev-med-050913-022545 · Cited by 471
Nguyen, H., Butow, P., Dhillon, H., & Sundaresan, P. (2021) · Journal of Medical Radiation Sciences · doi:10.1002/jmrs.421 · Cited by 351
Metadata
- Authors
- Judson, T. J., Bennett, A. V., Rogak, L. J., Sit, L., Barz, A., Kris, M. G., Hudis, C., Scher, H. I., Sabattini, P., Schrag, D., & Basch, E.
- Venue
- Journal of Clinical Oncology
- Published
- 2013-07-10
- Volume
- 31
- Issue
- 20
- Pages
- 2580-2585
- ISSN
- 0732-183X (ISSN-L)
- 1527-7755
- OpenAlex
- W2165712213
- Cited by
- 149
- References
- 7
- FWCI
- 5.85
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Feasibility of Long-Term Patient Self-Reporting of Toxicities From Home via the Internet During Routine Chemotherapy. https://app.cochat.ai/papers/10.1200/jco.2012.47.6804
- The paper
- Judson, T. J., Bennett, A. V., Rogak, L. J., Sit, L., Barz, A., Kris, M. G., Hudis, C., Scher, H. I., Sabattini, P., Schrag, D., & Basch, E. (2013). Feasibility of Long-Term Patient Self-Reporting of Toxicities From Home via the Internet During Routine Chemotherapy. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2012.47.6804
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.